Fueling the pipe
02.04.2012 - Belgian specialist for single-chain antibodies from camelidae Ablynx NV (Ghent) has strengthened its management with the appointment of Dr. Andreas Menrad as CSO.
Menrad is an expert for the progression of lead candidates into the clinic, and will closely collaborate with Ablynx CMO Josefin-Beate Holz, who is responsible for the firm's clinical Nanobody® programmes in hematological (ALX 0081/ALX0681) and immunological (ALX0061m ATN103)m ATN192) disorders as well as in oncology (ALX141, ALX651). Currently, Ablynx has five partnered preclinical drug programmes with Merck KGaA, while one Nanobody candidate is being developed with Novartis. Additionally, four preclinical programmes against undisclosed targets are being pursued in collaboration with Boehringer Ingelheim. Menrad will be responsible for the ongoing development of the Nanobody® platform, and will identify and prioritise new therapeutic programmes that Ablynx will pursue either on its own or with partners. The new CSO arrives from Genzyme, where he held the position of General Manager and Vice President of Antibody Therapeutics. Before joining Genzyme in 2007 Andreas Menrad worked with German Schering AG.